UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
You may also be interested in...
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
Companies operating in New Zealand will have six months to transition to Medsafe’s updated code on good manufacturing practice.
Alexion is collecting more evidence to convince NICE that its anticoagulant reversal agent is also cost-effective for intracranial hemorrhage.